Skip to main content
. 2018 Sep 12;13:176–188. doi: 10.1016/j.omtn.2018.08.014

Figure 2.

Figure 2

The Effects of MLN8237, Sorafenib, and Their Combination on Apoptosis and Cell Cycles of HepG2 and SMMC-7721 Cells

(A) HepG2 and SMMC-7721 cells were treated with sorafenib (2.5 and 5 μM), MLN8237 (0.3 μM), or both for 48 hr. Subsequently, flow cytometric analysis was conducted to monitor apoptosis. (B) Statistical analysis of the apoptosis results obtained from three independent flow cytometry assays. (C) HepG2 and SMMC-7721 cells were treated with sorafenib, MLN8237, or both for 48 hr. Flow cytometric analysis was then conducted to examine the cell cycle. (D) HepG2 cells were treated with sorafenib, MLN8237, or both for 48 hr. Western blotting was then performed to monitor the expression of p-Aurora, cleaved caspase-3, cleaved caspase-9, CDK4, and cyclin D1. Each experiment was performed at least three times. *p < 0.05; **p < 0.01.